Characterization of the DE-lncRNAs <i>PVT1</i>, <i>PCAT1</i>, and <i>PCAT10/CTBP1-AS</i> in TCGA sample.

Abstract

(A) Circle plot shows the percentage of 1,868 DE-lncRNAs that have been characterized based on related publications in PubMed (left). Red and gray indicate characterized and uncharacterized DE-lncRNAs, respectively. Characterized DE-lncRNAs are defined as the lncRNAs having at least one related publication. The characterized DE-lncRNAs were further ranked into three groups, with a darker shade of red indicating a greater number of related publications. Pie charts show the percentages of the characterized DE-lncRNAs with cancer-related (light blue) or CaP-related (dark blue) results among each group (right). (B) Crude and age- and Gleason score-adjusted expression levels of PVT1, PCAT1, and PCAT10 in AA and EA patients. (C) Expression levels of PVT1, PCAT1, and PCAT10 in prostate tumors and tumor-adjacent normal prostate tissues. (D) Percentile ranks of enrichment in AA men for PVT1, PCAT1, and PCAT10 across 33 TCGA cancer types. Color of bars reflects the fold change of expression (AA vs EA) ranks in a specific cancer type relative to others. High relative expression of PCAT1 and PCAT10 among AA men is specific to CaPs, while high relative expression of PVT1 occurs across cancer types. (E) AR binding signals at genomic loci surrounding or containing PCAT1 (left) and PCAT10 (right) from AR ChIP-seq analysis of two CaP cell lines (LNCaP, VCaP) treated with synthetic androgen agonists (R1881, DHT). (F) Expression levels of PVT1 and PCAT1 by copy number status (left). Number of men and frequency of SCNAs at 8q24.21 within categories of Gleason score and genetic ancestry (right).</p